Evidence map›Paper›PMID 32005669›Full record

ArticleThe Journal of biological chemistry2020

Serine phosphorylation of the small phosphoprotein ICAP1 inhibits its nuclear accumulation.

Valerie L Su, Bertrand Simon, Kyle M Draheim, David A Calderwood

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. ICAP-1 loss impairs CD8European journal of immunology · 2022
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Valerie L SuDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520.
Bertrand SimonDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520.
Kyle M DraheimDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520.
David A CalderwoodDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520; Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06520. Electronic address: david.calderwood@yale.edu.
Yale University · US

Funding

INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32GM007324 · NIGMS · YALE UNIVERSITY · PI BENNETT, ANTON M · 1987 to 2022
$6.2M
Molecular assembly and regulation of the cerebral cavernous malformation complexR01NS085078 · NINDS · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON, CALDERWOOD, DAVID A · 2013 to 2017
$1.8M
Phosphorylation of ICAP1 inhibits its nuclear accumulation to modulate integrin and CCM signalingF31HL143831 · NHLBI · YALE UNIVERSITY · PI SU, VALERIE LIAO · 2018 to 2020
$82k
NHLBI NIH HHS F31 HL143831NIGMS NIH HHS T32 GM007324NINDS NIH HHS R01 NS085078
6 · The paper itself

Abstract

Nuclear accumulation of the small phosphoprotein integrin cytoplasmic domain-associated protein-1 (ICAP1) results in recruitment of its binding partner, Krev/Rap1 interaction trapped-1 (KRIT1), to the nucleus. KRIT1 loss is the most common cause of cerebral cavernous malformation, a neurovascular dysplasia resulting in dilated, thin-walled vessels that tend to rupture, increasing the risk for hemorrhagic stroke. KRIT1's nuclear roles are unknown, but it is known to function as a scaffolding or adaptor protein at cell-cell junctions and in the cytosol, supporting normal blood vessel integrity and development. As ICAP1 controls KRIT1 subcellular localization, presumably influencing KRIT1 function, in this work, we investigated the signals that regulate ICAP1 and, hence, KRIT1 nuclear localization. ICAP1 contains a nuclear localization signal within an unstructured, N-terminal region that is rich in serine and threonine residues, several of which are reportedly phosphorylated. Using quantitative microscopy, we revealed that phosphorylation-mimicking substitutions at Ser-10, or to a lesser extent at Ser-25, within this N-terminal region inhibit ICAP1 nuclear accumulation. Conversely, phosphorylation-blocking substitutions at these sites enhanced ICAP1 nuclear accumulation. We further demonstrate that p21-activated kinase 4 (PAK4) can phosphorylate ICAP1 at Ser-10 both

Indexed as

Adaptor Proteins, Signal TransducingAmino Acid SequenceAnimalsCatalytic DomainCell NucleusCHO CellsCricetinaeCricetulusHumansKRIT1 ProteinMutagenesis, Site-Directedp21-Activated KinasesPhosphorylationSerineAdaptor Proteins, Signal TransducingITGB1BP1 protein, humanKRIT1 ProteinKRIT1 protein, humanp21-Activated KinasesPAK4 protein, humanPAK6 protein, humanSerinecell compartmentalizationcerebral cavernous malformationICAP1 (integrin cytoplasmic domain-associated protein-1)KRIT1 (Krev interaction trapped)nuclear importnuclear translocationnuclear transportnucleocytoplasmic shuttlingphosphoproteinphosphorylation

Identifiers

PMID32005669
PMCPMC7062153
OpenAlexW3003241878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.